Ningbo, Zhejiang, China, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Haoxin Holdings Limited (Nasdaq: HXHX) (“Haoxin” or the “Company”) today announced that on December 15, 2025, it received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the Minimum Bid Price Requirement set forth in Nasdaq Listing Rule 5550(a)(2). The notification was issued because the closing bid price of the Company’s Class A ordinary shares was below US$1.00 per share for ...

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it has regained compliance with the Nasdaq Stock Market (Nasdaq) continued listing standard for minimum share price under Rule 5450(a)(1) of the Nasdaq Listing Qualifications. On December 17, 2025, the Company received confirmation from the Listing Qualifications ...

Aditxt Inc. (NASDAQ:ADTX) shares surged 52.11% in after-hours trading to $2.16 on Tuesday following the company’s filing of a definitive proxy statement for a special stockholder virtual meeting scheduled for Jan. 30, 2026.Check out the current price of ADTX stock here.Multiple Shareholder ProposalsThe proxy statement outlines several critical proposals requiring shareholder approval. According to the Securities and Exchange Commission filing dated Tuesday, stockholders of record as of Dec. 5 will vote on N ...

Core Points - The company, Cypherpunk Technologies, Inc., formerly known as Leap Therapeutics, Inc., held a virtual Special Meeting of Stockholders on December 15, 2025 [1] - The meeting agenda included several proposals for stockholder approval [2] Proposal Summaries - A proposal to amend the company's Certificate of Incorporation to increase the total number of shares from 250 million to 500 million, with 490 million designated as common stock [3] - A proposal to authorize the Board to amend the Certificate of Incorporation for a reverse stock split at a ratio between 1:5 and 1:20, to be executed at the Board's discretion within one year [4] - A proposal to adopt a new 2025 Equity Incentive Plan [4] - A proposal to allow the company to issue shares exceeding 19.99% of the outstanding common stock to comply with NASDAQ listing rules upon the exercise of certain warrants [5]

Core Viewpoint - Noodles & Company is planning a reverse stock split to increase its share price after falling out of compliance with Nasdaq listing rules due to a share price below $1 for 30 consecutive business days [1][4]. Group 1: Reverse Stock Split Details - The reverse stock split is subject to shareholder approval, with eligible shareholders able to vote on February 4, 2026 [2]. - The board of directors has the flexibility to set the reverse split ratio between 1 for 2 and 1 for 15, and has one year post-vote to execute the split [3]. - The company may also opt not to execute the reverse stock split [3]. Group 2: Compliance and Share Price History - Noodles & Company received a second delisting warning on June 24, 2025, after a similar warning on December 24, 2024, indicating ongoing compliance issues [4]. - The share price was reported at 73 cents as of the last trading day [4]. Group 3: Shareholder Actions and Company Strategy - Activist investor Galloway Capital Partners, holding approximately 6.01% of shares, is advocating for the sale of the majority of Noodles & Company's restaurants [5]. - As of September 30, the company operated 349 company-owned restaurants and 86 franchised locations [5].

Core Viewpoint - Amcor plc will implement a 1-for-5 reverse stock split, reducing the number of outstanding shares from approximately 2.3 billion to about 461 million, effective January 15, 2026 [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split was approved by Amcor shareholders on November 6, 2025, and will be executed after trading closes on January 14, 2026 [1][3]. - Following the reverse stock split, Amcor's ordinary shares will trade on a split-adjusted basis, and the par value of the shares will increase to $0.05 [3]. - No fractional shares will be issued; instead, shareholders entitled to fractional shares will receive cash payments [4]. Group 2: Trading Information - Amcor ordinary shares will continue to trade on the New York Stock Exchange under the symbol "AMCR" but will have a new CUSIP number [5]. - CHESS Depositary Interests (CDIs) will also be consolidated on a 1-for-5 basis, with one CDI representing one ordinary share post-split [1][3]. Group 3: Company Overview - Amcor is a global leader in responsible packaging solutions, generating $23 billion in annualized sales from operations across over 400 locations in more than 40 countries [8]. - The company focuses on innovation and sustainability in packaging for various sectors, including nutrition, health, beauty, and wellness [8].

Core Insights - Tilray Brands, listed on NASDAQ as TLRY, is a significant player in the cannabis industry, focusing on the production and distribution of medical and recreational cannabis products [1][4] - The company executed a reverse stock split at a ratio of 10 for 1 on December 2, 2025, to consolidate shares and potentially stabilize its stock price [1][4] - Despite the reverse stock split, Tilray's shares have faced a substantial decline, with a nearly 40% loss in 2025 and a recent drop of over 20% in a trading session [2][4] Stock Performance - Following the reverse stock split, the total number of outstanding shares was reduced from approximately 1.16 billion to 116 million [2][4] - Currently, Tilray's stock is priced at $8.64, reflecting a 10.49% increase with a change of $0.82, and a trading volume of 5.37 million shares indicates active investor interest [3] - The stock has experienced significant fluctuations, with a low of $7.17 and a high of $8.95 in a single day, suggesting potential for further selling pressure [3]

Core Points - Sutro Biopharma, Inc. has announced a reverse stock split of its common stock at a ratio of 1-for-10, effective December 3, 2025, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1][2] Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 85,193,912 to about 8,519,392 [2] - Proportionate adjustments will be made to the exercise prices and number of shares underlying the Company's outstanding equity awards and incentive plans [2] - No fractional shares will be issued; stockholders entitled to fractional shares will receive shares rounded up to the nearest whole share [3] Group 2: Company Overview - Sutro Biopharma is focused on developing next-generation antibody-drug conjugates (ADCs) aimed at improving cancer treatment [4] - The Company utilizes a cell-free platform to produce ADCs that enhance drug exposure, minimize side effects, and target a broader range of tumor types [4] - Sutro's pipeline includes single- and dual-payload ADCs targeting large oncology markets with significant unmet needs [4]

Core Viewpoint - Tilray's stock experienced a significant decline of 19.4% following the announcement of a 1-for-10 reverse stock split, which will reduce the total share count from approximately 1.16 billion to 116 million shares [1][3]. Summary by Sections Reverse Stock Split Details - Tilray has chosen the less drastic option of a 1-for-10 reverse stock split, meaning investors will own 10% fewer shares than before [3]. - The reverse split will take effect after trading on December 1, with shares resuming trading at an estimated price of $8.10 on December 2, based on the current price of $0.81 [4][8]. Implications of the Reverse Split - A reverse stock split does not fundamentally change the company's business but increases the price per share, which can help avoid delisting risks [5]. - The reverse split indicates that Tilray has not been able to increase its share price through business growth, suggesting potential reasons for investors to consider selling [6]. Investment Considerations - Analysts have identified ten stocks they believe are better investment opportunities than Tilray, indicating a lack of confidence in Tilray's current market position [9].

Core Viewpoint - Rubico Inc. has announced a 1-for-30 reverse stock split to increase the market price of its common stock and maintain compliance with Nasdaq's listing requirements [7]. Group 1: Reverse Stock Split Details - The reverse stock split will be effective on December 2, 2025, with common shares trading on a split-adjusted basis under the symbol "RUBI" [2]. - Every 30 issued and outstanding common shares will convert into 1 common share, without changing the par value or the total number of shares authorized [3]. - As of November 20, 2025, the company had 61,444,087 outstanding common shares, which will be reduced to approximately 2,048,136 shares after the split [4]. Group 2: Shareholder Impact - The reverse stock split will not affect shareholders' ownership percentages, except for fractional shares, and will not impact the company's market capitalization or voting rights [4]. - No fractional shares will be issued; instead, shareholders entitled to fractional shares will receive a cash payment based on the closing price of the common shares on December 1, 2025 [5]. - Shareholders with shares held in book-entry form or through a bank or broker will see the impact reflected in their accounts without needing to take action [6]. Group 3: Company Overview - Rubico Inc. is a global provider of shipping transportation services, specializing in vessel ownership, and operates two modern, fuel-efficient Suezmax tankers [8].